Human Regenerative Technologies

Human Regenerative Technologies is a private regenerative medicine and tissue-processing company focused on human amniotic and placental allografts for wound care and related clinical applications. The company operates as an AATB-accredited and FDA-registered tissue bank and develops shelf-stable placental tissue products processed under Section 361 of the Public Health Service Act and 21 CFR Part 1271. Its core differentiator is the proprietary HydraTek preservation and processing platform, including the BioAware preservation system, which is designed to maintain native tissue integrity, hydration, handling characteristics, and safety. HRT markets commercial allograft products such as WoundFix, WoundPlus, and E-Graft for acute and chronic wound management. The company is majority owned by Skye Biologics Holdings and serves as a tissue-processing arm within a broader vertically integrated regenerative medicine strategy.